Terms: = Ovarian cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
9631 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
[TBL] [Abstract] [Full Text] [Related]
3. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
4. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
5. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
6. Imaging for local recurrence of breast cancer.
Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
[TBL] [Abstract] [Full Text] [Related]
7. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
8. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
9. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
10. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
11. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM; Savolainen K; Virtanen T; Ryyppö L; Selin H; Martikainen P; Staff S; Kivinummi K; Sipola J; Vuorinen J; Nikkola J; Nykter M; Auranen A; Annala M
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38580393
[TBL] [Abstract] [Full Text] [Related]
12. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
13. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract] [Full Text] [Related]
14. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
15. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract] [Full Text] [Related]
16. Epithelial ovarian cancer in younger age versus older age groups: Survival and clinicopathological features.
Kongkamsuan W; Boonyapipat S
J Cancer Res Ther; 2024 Jan; 20(1):363-368. PubMed ID: 38554347
[TBL] [Abstract] [Full Text] [Related]
17. Characteristics of patients with late recurrence endometrial cancer.
Çakır İ; Gülseren V; Özdemir İA; Abacı H; Talu ECK; Çakır ZE; Ata C; Kuru O; Gökçü M; Sancı M; Güngördük K
J Cancer Res Ther; 2024 Jan; 20(1):232-237. PubMed ID: 38554326
[TBL] [Abstract] [Full Text] [Related]
18. Single-cell transcriptomics reveals comprehensive microenvironment and highlights the dysfuntional state of NK cells in endometrioid carcinoma.
Shi W; Wu W; Wang J; Meng X
Medicine (Baltimore); 2024 Mar; 103(13):e37555. PubMed ID: 38552055
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
20. CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells.
Zhang Q; Zhang R; Li Y; Yang X
J Ovarian Res; 2024 Mar; 17(1):68. PubMed ID: 38539247
[TBL] [Abstract] [Full Text] [Related]
[Next]